Affiliation:
1. Department of Pharmaceutical Sciences University at Buffalo, The State University of New York Buffalo New York USA
Abstract
AbstractPhysiological determinants of drug dosing (PDODD) are a promising approach for precision dosing. This study investigates the alterations of PDODD in diseases and evaluates a variational autoencoder (VAE) artificial intelligence model for PDODD. The PDODD panel contained 20 biomarkers, and 13 renal, hepatic, diabetes, and cardiac disease status variables. Demographic characteristics, anthropometric measurements (body weight, body surface area, waist circumference), blood (plasma volume, albumin), renal (creatinine, glomerular filtration rate, urine flow, and urine albumin to creatinine ratio), and hepatic (R‐value, hepatic steatosis index, drug‐induced liver injury index), blood cell (systemic inflammation index, red cell, lymphocyte, neutrophils, and platelet counts) biomarkers, and medical questionnaire responses from the National Health and Nutrition Examination Survey (NHANES) were included. The tabular VAE (TVAE) generative model was implemented with the Synthetic Data Vault Python library. The joint distributions of the generated data vs. test data were compared using graphical univariate, bivariate, and multidimensional projection methods and distribution proximity measures. The PDODD biomarkers related to disease progression were altered as expected in renal, hepatic, diabetes, and cardiac diseases. The continuous PDODD panel variables generated by the TVAE satisfactorily approximated the distribution in the test data. The TVAE‐generated distributions of some discrete variables deviated from the test data distribution. The age distribution of TVAE‐generated continuous variables was similar to the test data. The TVAE algorithm demonstrated potential as an AI model for continuous PDODD and could be useful for generating virtual populations for clinical trial simulations.
Reference37 articles.
1. National Institutes of Health.The promise of precision medicine. Accessed October 8 2023.https://www.nih.gov/about‐nih/what‐we‐do/nih‐turning‐discovery‐into‐health/promise‐precision‐medicine#:~:text=This%20one%2Dsize%2Dfits%2D genes%2C%20environments%2C%20and%20lifestyles2023.
2. Food and Drug Administration.Precision medicine. Accessed October 10 2023.https://www.fda.gov/medical‐devices/in‐vitro‐diagnostics/precision‐medicine2018.
3. Generative adversarial networks for modelling clinical biomarker profiles with race/ethnicity
4. Generative models for age, race/ethnicity, and disease state dependence of physiological determinants of drug dosing;Nair R;J Pharmacokinet Pharmacodyn,2023
5. Generative adversarial networks;Goodfellow IJ;arXiv,2014